

GALAPAGOS

Limited Liability Company
Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
Company number: 0466.460.429
RLE Mechelen
(the "**Company**")

Special report of the Board of Directors in accordance with Article 596 and 598 of the Belgian Companies Code

Cancellation of the preferential subscription rights of the existing shareholders in the framework of Warrant Plan 2012

1 Introduction: subject matter of this report

This report is established on 12 July 2012 by the Board of Directors of the Company in accordance with the provisions of Articles 596 and 598 of the Belgian Companies Code.

In accordance with said articles, the subject matter of this report is to provide justification for the proposal to cancel the preferential subscription rights for the benefit of the individuals mentioned in this report. The preferential subscription rights will be cancelled in connection with the issuance of warrants relating to new shares that will in all aspects be identical to the existing shares of the Company. This issuance of warrants will be implemented by the Board of Directors within the framework of the authorized capital as renewed by the extraordinary general shareholders' meeting of the Company of 23 May 2011. In this context, the Board of Directors further refers to the report the Board has established on the date hereof in accordance with Article 583 of the Belgian Companies Code.

The Board of Directors proposes to issue, within the framework of the authorized capital, a maximum of 530,140 naked warrants in the framework of the Warrant Plan 2012.

This report elaborates on the proposed exercise price of the warrants and the financial consequences of the proposed transaction for the Company's shareholders. The Company will ask its Statutory Auditor (Deloitte Bedrijfsrevisoren represented by Mr Gino Desmet) to provide his report in accordance with Articles 596 and 598 of the Belgian Companies Code, in connection with this matter.

2 Explanation in connection with the authorized capital

The Company's extraordinary shareholders' meeting has resolved on 23 May 2011 to renew the authorization to the Board of Directors with respect to the use of the authorized capital. By this renewed authorization the Board was authorized to increase the share capital in one or more times with an amount of 142,590,770.44 Euro. This authorization is split in two tranches. The authorization with respect to the first tranche of 25% (35,647,692.61 Euro) of the authorized capital can be used by the Board of Directors by normal resolution. The authorization with respect to the second tranche of 75% (106,943,077.83 Euro) of the

authorized capital can only be used upon unanimous resolution of the Board of Directors in which all directors are present or represented. Furthermore, this second tranche can only be used in the context of the following purposes:

- (i) the entire or partial financing of a transaction through the issue of new shares of the Company, whereby "transaction" is defined as a merger or acquisition (in shares or cash), a corporate partnership, and an in-licensing deal,
- (ii) the issue of warrants in the framework of the remuneration policy for employees, directors and independent consultants of the Company and its subsidiaries, and
- (iii) the defence of the Company against a hostile take-over bid, and
- (iv) strengthening of the cash position of the company.

The renewed authorization to use the authorized capital is valid for a period of five years as from 23 May 2011. The Board of Directors may, in the context of the authorized capital, issue shares with or without voting rights. The Board may also issue convertible bonds or warrants. The Board may issue shares as consideration for contributions in cash or in kind, with or without a share issue premium. If the Board asks a share issue premium, such premium shall be booked on a non-available reserve account. Such account can only be reduced or transferred after a decision of an extraordinary shareholders' meeting of the Company adopted in the manner required for amending the articles of association.

The Board may, within the authorized capital, limit or cancel the preferential subscription rights of the existing shareholders but only in the interest of the Company. Furthermore, the Board has the authority to cancel the preferential subscription rights of the existing shareholders for the benefit of certain persons, other than employees of the Company or its subsidiaries.

The currently proposed conditional capital increase, under the authorized capital and with cancellation of the preferential subscription rights, by the in principle decision of the Board to issue maximum 530,140 warrants in the framework of the Warrant Plan 2012, is therefore still within the limits of the total authorization of the authorized capital, taking into account the current accounting par value of €5.41 per share.

3 Issuance price and exercise price of the warrants

In connection with the proposed issuance of the warrants no issuance price will be paid. The warrants will be granted for free to the beneficiaries of the plan.

Pursuant to Article 598 of the Belgian Companies Code and as (i) the shares of the Company are listed or traded on a regulated market on the date of the offer and (ii) not all beneficiaries are employees of the Company and/or its subsidiaries, the exercise price will at least be equal to the average of the closing price of the share of the company during the last thirty (30) days preceding the date of the offer. The exercise price shall in no event be lower than the accounting par value (rounded up to the higher eurocent) of the shares on the date of the issuance of the warrants.

4 Financial consequences of the transaction for the shareholders

4.1 Concerning the evolution of the share capital and the profit sharing

The share capital of the Company, at the date of this report, amounts to 413,770,414.14 Euro and it is represented by 26,577,554 shares, each share representing an equal part of the share capital.

In the event that warrants of the Warrant Plan 2012 would be exercised during their exercise term, the share capital of the Company will be increased by 5.41 Euro per exercised warrant.

In the event all 530,140 warrants issued under the Warrant Plan 2012 would be exercised and, consequently, 530,140 new shares would be issued, a dilution will occur (taking into account the number of shares at the date of this report) for the existing shares in the profit of the Company of (rounded off) 1.96%.

In 2002, 2005, 2006, 2007, 2008, 2009, 2010 and 2011 the Company already approved different warrant plans under which warrants are still outstanding. The exercise of all warrants still outstanding under these plans can possibly lead to the creation of up to 3,166,362 additional shares. In the event all these warrants, granted and still capable of exercise, would be exercised, the dilution resulting from the present issuance of warrants will be of maximum (rounded off) 1.75%.

At the date of this report no warrants are available for offering under the already existing warrant plans of the Company.

As the exercise price of the warrants under the Warrant Plan 2012 cannot be lower than the accounting par value of the share of the Company, the exercise of these (maximum) 530,140 warrants will have no effect on the accounting par value of the share.

4.2 Effect on the equity of the Company

In the event all 530,140 warrants would be exercised, there would be an increase of the equity of the Company for an amount equal to the product of 530,140 and the exercise price per warrant, provided, however, that this increase cannot be lower than 2,868,057.40 Euro (being the number of warrants multiplied by (rounded up) 5.41 Euro, i.e. the accounting par value of the share of the Company at the date of this report). If the exercise price of a warrant is higher than the equity value per share and the warrant is *de facto* exercised, there would be a positive effect on the equity value per share for the existing shareholders.

4.3 Potential financial dilution resulting from the possible future issuance of shares emanating from the exercise of warrants under the Warrant Plan 2012

To the extent that the issuance price of the new shares that will possibly be issued as a result of the exercise of warrants under the Warrant Plan 2012 is lower than the market price of the shares at the moment of the issuance, the existing shareholders will be confronted with a financial dilution as in such case the warrant holders subscribe to new shares at a lower price than the existing shares. This dilution is calculated by subtracting the value per share after the issuance of the new shares from the market price of the share at the moment of the issuance of the new shares. The result is then brought in relation to the original market price.

4.4 Other accounting (IFRS) and financial consequences of the offering of warrants

At the occasion of the acceptance of the offered warrants the Company will determine a fair value for the warrants based on actuarial methods that are commonly used for this purpose and this fair value will be accounted for over the vesting period of the warrants in accordance with the relevant warrant plan. This fair value can only be determined at the date of acceptance of the warrants. It will be determined taking into account the following parameters: (i) the market price of the share of the Company at the date of the offer; (ii) the exercise price of the warrants; (iii) the expected volatility of the share of the Company; and (iv) the exercise term of the warrants (i.e. 8 years).

5 Motivation for the cancellation of the preferential subscription rights

The Board of Directors of the Company anticipates that the granting of warrants to employees, directors and independent consultants active within the Company or its subsidiaries will result in an enhanced motivation of the beneficiaries of these warrants and that it will stimulate a sharpened attention for the interests of the company and its shareholders.

6 Individuals, other than employees, for whose benefit the preferential subscription rights are cancelled

Under the Warrant Plan 2012, the following number of warrants will be offered to persons who are no employees of the Company and/or of its subsidiaries:

- Mr Onno van de Stolpe (executive director and CEO): 100,000 warrants;
- Dr Raj Parekh (non-executive director): 3,780 warrants;
- Mr Ferdinand Verdonck (independent non-executive director): 3,780 warrants;
- Dr Harrold van Barlingen (non-executive director): 2,520 warrants;
- Dr Werner Cautreels (independent non-executive director): 2,520 warrants;
- Mr Howard Rowe (non-executive director): 2,520 warrants;
- Dr Vicki Sato (independent non-executive director): 2,520 warrants;
- Mr Guillaume Jetten (independent consultant / CFO): 20,000 warrants; and
- Dr Piet Wigerinck (independent consultant / CSO): 50,000 warrants.

The attribution of warrants to directors is nevertheless subject to approval by the Extraordinary Shareholders' Meeting of the Company

English translation for information purposes only

Made and approved on 12 July 2012.

For the Board of Directors of the Company,

Onno van de Stolpe
Director

Ferdinand Verdonck
Director